Cellular Dynamics International

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Retrieved on: 
Thursday, November 9, 2023
Incidence, IPSC, Therapy, Cellular Dynamics International, Prevalence, Inflammation, Data, Rheumatoid arthritis, Cell, Research, ASH, Century, NK, Partnership, Autoimmune disease, Multiple sclerosis, Autoimmunity, Cancer, Patient, Lupus, Pharmaceutical industry, Vaccine

Treatment of autoimmune disease is currently limited to symptom management, and includes correcting resulting deficiencies in the body, along with reducing inflammation and the immune response.

Key Points: 
  • Treatment of autoimmune disease is currently limited to symptom management, and includes correcting resulting deficiencies in the body, along with reducing inflammation and the immune response.
  • iPSCs have the capability to self-renew and differentiate into key cell types, providing regenerative and immune-modulating properties as a treatment modality.
  • These agreements enable further evaluation of Century’s iPSC-derived NK, T cell, and monocyte/macrophage platforms,” said Hy Levitsky, M.D., president of research and development, Century Therapeutics.
  • We are committed to ensuring that iPSC-derived therapeutics realize their full potential, and we look forward to supporting Century Therapeutics’ progress.”

Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases

Retrieved on: 
Thursday, June 8, 2023
Tissue, Heart, Versant, Capsid, Broad Institute, University, DM1, Pardis Sabeti, Cardiac muscle, Research, MIT, FSHD, RNA, Harvard University, AAV, Facioscapulohumeral muscular dystrophy, Patient, Machine learning, SAN, Cellular Dynamics International, Therapy, X-linked myotubular myopathy, Safety, Pharmaceutical industry, Vaccine, Cell

SAN DIEGO, June 8, 2023 /PRNewswire/ -- Kate Therapeutics Inc. ("KateTx"), a next-generation gene therapy company, today emerged from stealth mode with a $51 million Series A financing co-led by founding investor Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM), the details of which are described in a separate press release issued today.

Key Points: 
  • "We are excited to announce KateTx's launch and what this means for patients suffering from muscle and heart diseases," said Kevin Forrest, Ph.D., president, CEO and a director of KateTx.
  • "KateTx is applying novel capsid and cargo technology platforms to enable skeletal and cardiac muscle targeting and liver de-targeting.
  • KateTx's current focus is identifying and advancing clinical candidates for DM1 and FSHD, as well as for other genetic muscle and heart diseases.
  • "With this Series A financing and licensing agreement, KateTx will be able to progress its deep pipeline of internal programs."

Global Induced Pluripotent Stem Cell (iPSC) Industry Report 2023: Profiles Leading Market Competitors, Including FUJIFILM CDI, ReproCELL, Evotec, Ncardia, and Axol Bioscience - ResearchAndMarkets.com

Retrieved on: 
Monday, February 13, 2023
Health, Stem Cells, Macular degeneration, Regenerative medicine, Cellular Dynamics International, B cell, Toxicology, Game Industry Report Magazine, Human, Thermo Fisher Scientific, Drug development, Therapy, IPSC, Medicine, Cell, 3D bioprinting, Safety, University of Wisconsin–Madison, Patient, CRISPR, Clinical trial, CLI, University, CDI, Research, MSC, Tissue engineering, Merck, Graft-versus-host disease, Kyoto University, Personalized medicine, Disease, Partnership, OA, COVID-19, Drug discovery, Microsoft Exchange Server, Osteoarthritis, Pharmaceutical industry, Veterinary medicine, Mobile phone, Fine chemical

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Personalized Medicine:The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single base changes) in many cell types.
  • Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

Retrieved on: 
Thursday, January 5, 2023
IPSC, GMP, Research, Cellular Dynamics International, Potency (pharmacology), Novo Nordisk, Disease, Conditional sentence, Cell, Pharmaceutical industry, Nordisk

MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

Key Points: 
  • MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.
  • Under the agreement, Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies.
  • “FUJIFILM Cellular Dynamics is a global leader in the development and manufacturing of GMP-grade iPSCs for cell therapy applications.
  • Our goal is to drive the iPSC field forward by building strategic partnerships,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics.

FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer

Retrieved on: 
Thursday, September 15, 2022
National, Retinitis pigmentosa, Health, IPSC, National Center for Advancing Translational Sciences, Molecular biology, Gene editing, Potency (pharmacology), Knowledge, Cellular Dynamics International, Fujifilm, Patient, Sanford Burnham Prebys Medical Discovery Institute, Technology, NCATS, Quality of life, CDMO, Degenerative disease, University, Research, GLOBE, Neuroanatomy, Drug discovery, NIH, Pfizer, Mobile phone, Pharmaceutical industry, Innovation

MADISON, Wis., Sept. 15, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singe, M.D., as chief scientific officer effective September 12.

Key Points: 
  • MADISON, Wis., Sept. 15, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singe, M.D., as chief scientific officer effective September 12.
  • We are thrilled to welcome Dr. Singe to the FUJIFILM Cellular Dynamics family, said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics, Inc. Dr. Singe brings over 20 years of experience in cell and molecular biology, and extensive stem cell expertise, which will be instrumental as FUJIFILM Cellular Dynamics expands our application of leading-edge iPSC technologies to continue innovating in this field.
  • Prior to joining FUJIFILM Cellular Dynamics, Dr. Singe served as the inaugural director of the Stem Cell Translation Laboratory (SCTL) at the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH).
  • FUJIFILM Cellular Dynamics is a pioneer in developing iPSC technology for scientific and translational research, said Dr. Singe.

Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board

Retrieved on: 
Tuesday, September 13, 2022
Therapy, Cellular Dynamics International, Science Publishing Group, IPSC, Wisconsin National Primate Research Center, Medical laboratory, United States Air Force Scientific Advisory Board, Potency (pharmacology), Augustus A. Bird, Immunology, Kyiv Medical University of UAFM, Haematopoiesis, Immunotherapy, Patient, Cell, Solution, Purdue University, Seattle, Pathology, Research, GLOBE, University, Precision medicine, CAR, Genomics, Pharmaceutical industry, Vaccine, Umoja

"We are excited to welcome Igor to Umojas Scientific Advisory Board.

Key Points: 
  • "We are excited to welcome Igor to Umojas Scientific Advisory Board.
  • Igors appointment comes at an important time as Umoja continues to advance our iPSC-based synthetic receptor enabled differentiation platform into the clinic.
  • Dr. Slukvin brings his expertise to the Umoja Scientific Advisory Board from the University of Wisconsin, Madison where he serves as the first Henry Pitot Professor of Pathology and Laboratory Medicine and Professor of Cell and Regenerative Biology.
  • Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy.

Hong Kong International Jewellery Show and International Diamond, Gem & Pearl Show open at end of July

Retrieved on: 
Thursday, July 14, 2022
Diamond, Dai, Gems, People, Zero, Convention center, Equipment, Exhibition, LinkedIn, Future, Silver, Hong Kong Trade Development Council Trade Fairs, ITC, Betta Home Living, The World of Glamour, Communication, Wrist, Nature, Wine, Brand, CVS, Simply, Ruby, Secret Garden, HKTDC, SME, Lists of people executed in the United States, Collection, Neck, Glass, Ageing, Adult, Creation, Tradition, Zuri, Cooking, Commerce, Hong Kong Fashion Week for Fall/Winter, Public affairs, Fashion, Hexagon, Hong Kong Trade Development Council, Social media, Animation, Brooch, Beauty, Gold, Cellular Dynamics International, Facebook, Government, Yoga, HK, Research, Twitter, Jewellery, Hatmaking, Tutoring, Gemstone, Cassette tape, Science

HONG KONG, July 14, 2022 - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC), the 38th HKTDC Hong Kong International Jewellery Show and 8th HKTDC Hong Kong International Diamond, Gem & Pearl Show will be held at the Hong Kong Convention and Exhibition Centre from 29 July to 2 August, presenting a dazzling array of exquisite jewellery and jewellery-making materials.

Key Points: 
  • HONG KONG, July 14, 2022 - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC), the 38th HKTDC Hong Kong International Jewellery Show and 8th HKTDC Hong Kong International Diamond, Gem & Pearl Show will be held at the Hong Kong Convention and Exhibition Centre from 29 July to 2 August, presenting a dazzling array of exquisite jewellery and jewellery-making materials.
  • Pictured at the press conference today are Sophia Chong, Lawrence Ma and members of the HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem & Pearl Show Fair Organising Committee.
  • The main focus of the Hong Kong International Diamond, Gem & Pearl Show is on quality jewellery materials.
  • - Hong Kong International Jewellery Show: https://hkjewelleryshow.hktdc.com
    - Hong Kong International Diamond, Gem & Pearl Show: https://hkdgp.hktdc.com
    The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade.

Global Critical Logistics Acquires Spanish Forwarder Asesores de Flete as Part of Ongoing Growth Strategy

Retrieved on: 
Wednesday, June 1, 2022
Other Transport, Trucking, Rail, Events, Concerts, Maritime, Logistics, Supply Chain Management, Transport, Entertainment, Transport, Sport, GCL, Partnership, Central, Customs, Solution, Cau del Cargol, ATL, Acquisition, ADF, Classic Rock (Dial Global radio network), Music festival, Television, Cellular Dynamics International, Music, Tourism

Global Critical Logistics (GCL) has acquired Madrid, Spain-based forwarder Asesores de Flete, S.A. (ADF), an experienced, non-asset-based provider of mission-critical logistics services to the live event, entertainment, sports, and broadcast industries.

Key Points: 
  • Global Critical Logistics (GCL) has acquired Madrid, Spain-based forwarder Asesores de Flete, S.A. (ADF), an experienced, non-asset-based provider of mission-critical logistics services to the live event, entertainment, sports, and broadcast industries.
  • Together with Rock-it Globals extensive presence in Latin America, the ADF acquisition solidifies Rock-it Globals in-house capabilities to serve customers throughout the Spanish-speaking world.
  • The acquisition of ADF builds on our strategy of enhancing capabilities to target customers in high growth industries such as live events, music touring, sports, broadcast, and film and television production.
  • GCL has offices in North, Central and South America, Europe, the Middle East, and Asia Pacific, augmented by a network of long-term partner agents specializing in critical logistics.

Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board

Retrieved on: 
Monday, May 23, 2022
Capital, Disease, Stanford University, Research, Epidemiology, Hotel manager, University, Adela Investment Company, Cancer, SAB, Oncology, Master of Science, Knight Cancer Institute, UCL, Annual Review of Cancer Biology, Peter MacCallum Cancer Centre, Medical statistics, University College London, Cellular Dynamics International, Genomic Health, Board, Celebrity board director, Exact sciences, Department, DNA, Genome, Doctor of Philosophy, Multimedia, MBBS, Leukemia Research, Affymetrix, Leukemia, Machine learning, Coronavirus Scientific Advisory Board (Turkey), Assistant, Business development, View, Cancer research, Marker beacon, Dean (education), RA, MS, Genomics, Technology, Board of directors, Diagnosis, CEO, Management, Radiology, Professor, Medicine, FRACP, MD

TORONTO, May 23, 2022 /PRNewswire/ -- Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.

Key Points: 
  • The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.
  • "I am thrilled to welcome Chris Parker, Chief Business Officer to Adela's Executive Team," said Scott Bratman, Chief Executive Officer at Adela.
  • Chris Parker joins Adela from Exact Sciences, where he served as Vice President, Business Development and was responsible for inorganic growth strategy.
  • Adela has also formed a Scientific Advisory Board (SAB) with deep expertise in cancer biology, machine learning, and cancer screening.

Clade Therapeutics Announces the Appointment of Derek Hei, Ph.D., as Chief Technology Officer

Retrieved on: 
Thursday, March 10, 2022
Bristol Myers Squibb, B cell, Senior, University, Terra Venture Partners, Company, Cellular Dynamics International, Chemistry, Cell, Gene, GLOBE, Patient, SVP, Bluerock Creek, Emerson Collective, Technology, Berkeley, University of Wisconsin–Madison, CTO, Vertex, Therapy, Bachelor of Science, IPSC, NK, Biotechnology, Chemical engineering, CGMP, CMC, Adult, Vertex Pharmaceuticals, Pharmaceutical industry, Clade, Science

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced the appointment of Derek Hei, Ph.D., as its Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced the appointment of Derek Hei, Ph.D., as its Chief Technology Officer (CTO).
  • Dereks extensive experience establishing manufacturing operations for stem cell-based medicines makes him an ideal fit to lead these efforts at Clade, said Chad Cowan, Ph.D., Chief Executive Officer of Clade Therapeutics.
  • Clade is led by an exceptional team of scientists and bioentrepreneurs with deep experience translating their foundational discoveries into differentiated therapeutic candidates.
  • Clade Therapeutics mission is to discover and deliver next generation cell medicines to improve the lives of patients in need.